Cardiac surgery fibrinogen concentrate use — the application of fibrinogen replacement therapy in cardiac surgery patients experiencing coagulopathic bleeding from cardiopulmonary bypass-induced fibrinogen consumption, hemodilution, and hypothermia — represents the highest-volume commercial application, with the Fibrinogen Concentrate Market reflecting cardiac surgery as the commercial volume anchor.

Cardiopulmonary bypass fibrinogen depletion — the contact of blood with the bypass circuit surface activating coagulation and consuming fibrinogen, the hemodilution from pump priming volume, and the heparin-mediated coagulopathy collectively reducing fibrinogen levels to critical thresholds (below one-point-five g/L) in approximately twenty to thirty percent of cardiac surgery patients. Complex procedures (valve replacement, aortic arch surgery, redo sternotomy) associated with greater fibrinogen depletion and more severe bleeding.

FIBRES randomized trial — the landmark Canadian randomized trial demonstrating fibrinogen concentrate non-inferior to cryoprecipitate for bleeding control in cardiac surgery while offering advantages of faster administration and standardized dosing — providing the evidence supporting fibrinogen concentrate adoption in cardiac surgery. The FIBRES trial's finding that fibrinogen concentrate achieved equivalent hemostasis with approximately fifty percent fewer blood product units (from cryoprecipitate pooling requirements) creating the practical advantage.

ROTEM-guided fibrinogen replacement — the point-of-care ROTEM (Rotational Thromboelastometry) FIBTEM assay guiding fibrinogen concentrate dosing in cardiac surgery — creating the diagnostic-therapeutic algorithm that drives rational fibrinogen concentrate use. The FIBTEM maximum clot firmness (MCF) below seven millimeters triggering fibrinogen concentrate with dosing calculated to restore FIBTEM MCF above ten millimeters creating the evidence-based algorithm.

Do you think ROTEM-guided fibrinogen concentrate therapy will become the universal standard for cardiac surgery bleeding management, replacing empirical cryoprecipitate use?

FAQ

How does cardiopulmonary bypass affect fibrinogen levels? CPB effects on fibrinogen: hemodilution (pump prime volume 1.5-2L dilutes all coagulation factors proportionally); contact activation (blood-circuit contact activates coagulation consuming fibrinogen); fibrinolysis (CPB activates fibrinolysis degrading fibrin clots); hypothermia (enzyme function impaired); heparin (anticoagulation prevents fibrin formation but not consumption by activated coagulation); result: fibrinogen typically falls twenty to fifty percent during uncomplicated CPB; complex procedures (repeat surgery, prolonged bypass, circulatory arrest): fibrinogen may fall to critical levels (<1.5 g/L); bleeding risk dramatically increases below this threshold.

What is ROTEM FIBTEM and how does it guide fibrinogen replacement? FIBTEM (Functional FIbrinogen TEst by thromboelastometry): ROTEM assay with cytochalasin D blocking platelet contribution; measures only fibrin-based clot strength; key parameter: FIBTEM MCF (Maximum Clot Firmness) in millimeters; normal: 9-25mm; critical threshold: <7mm indicating severe fibrinogen deficiency; clinical algorithm: FIBTEM MCF < 7-9mm plus active bleeding → administer fibrinogen concentrate; dose calculation: (target FIBTEM MCF - current FIBTEM MCF) × 1.5 = grams of fibrinogen concentrate; goal: restore FIBTEM MCF to >10mm; advantages: bedside real-time testing; fifteen-twenty minute result; guides individualized dosing avoiding over/under-treatment.

#FibrinogenConcentrate #CardiacSurgeryFibrinogen #CPBcoagulation #ROTEMfibrinogen #FIBTEMguided #CardiacHemostasis